Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. on December 3, 2021, covering events occurring on December 2, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CRDF.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
On December 2, 2021, the company granted non-qualified stock option awards to purchase an aggregate of 200,112 shares of common stock to two new employees. These grants were made as inducements material to the employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the stock option grant event.
Key Facts for Investor Verification
- 200,112 stock options were granted to two new employees on December 2, 2021.
- The grants were structured as inducements required for employment under Nasdaq rules.
- No financial performance data is included in this specific filing.